The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease
- 1 July 1995
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 6 (6) , 543-549
- https://doi.org/10.1093/oxfordjournals.annonc.a059242
Abstract
Relapsed or refractory Hodgkin's disease (HD) patients were treated with an intensive salvage regimen (MINE) prior to high-dose therapy (HDT) with hematopoietic stem cell support. One hundred HD patients who either failed to respond to a front-line chemotherapy regimen (induction failure, n—41) or relapsed (untreated relapse, n—54; resistant relapse, n—5) were treated with the MINE regimen. Each course of MINE comprised mitoguazone 500 mg/m2 on days 1 and 5, ifosfamide 1500 mg/m2/d from day 1 to day 5, vinorelbine (Navelbine®) 15 mg/m2 on days 1 and 5, and etoposide 150 mg/m2/d from day 1 to day 3. At least two courses were given at 4-week intervals. Then, 72 patients received HDT followed by hematopoietic stem cell support. After MINE salvage, 34 patients achieved a complete response (CR) and 39 a partial response, yielding an overall response rate of 75%. Patients with untreated relapse had a 92.5% response rate and those with resistant relapse or induction failure a 53% response rate. A total of 58 patients reached a CR at the end of all treatments; 12 of them relapsed. Sixty-six patients were alive with a median follow-up of 26 months, including 46 patients in CR. The 2-year survival rate for the entire group was 59%. By univariate analysis, patients with an interval between their last treatment and salvage longer than 12 months, untreated relapse, or good performance status at salvage are shown to have longer survivals. The main toxic effects were neutropenia, thrombo-cytopenia, and infectious episodes. Three patients died of MINE-related complications and three after HDT. Given early in the course of progressive HD, the MINE regimen reduced tumor burden in a high proportion of patients with relapsed or refractory disease. Responding patients further intensified with HDT have a better outcome than those who have not responded to salvage treatment.Keywords
This publication has 16 references indexed in Scilit:
- High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.Journal of Clinical Oncology, 1993
- High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease.Journal of Clinical Oncology, 1992
- Mini‐BEAM followed by BEAM and ABMT for very poor risk Hodgkin's diseaseBritish Journal of Haematology, 1992
- Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.Journal of Clinical Oncology, 1992
- Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's diseaseAnnals of Oncology, 1991
- Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantationBlood, 1989
- Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantationBlood, 1989
- MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease.Journal of Clinical Oncology, 1987
- High-Dose Cyclophosphamide, Carmustine, and Etoposide and Autologous Bone Marrow Transplantation for Relapsed Hodgkin's DiseaseAnnals of Internal Medicine, 1986
- MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease.Journal of Clinical Oncology, 1985